Alpha Tau Medical Ltd. announces acceptance of its abstract on Alpha DaRT combined with pembrolizumab in elderly HNSCC patients for podium presentation at the AHNS 12th International Conference on Head and Neck Cancer.
Key takeaways
Abstract from Hadassah Medical Center trial evaluating Alpha DaRT plus pembrolizumab in elderly patients with locally advanced/metastatic HNSCC selected for podium presentation at AHNS conference July 18-22, 2026 in Boston.
Presentation scheduled for July 21, 2026, 10:30 AM-12:00 PM during Proffered Papers session on Radiation and Adjuvant Therapies.
Presents complete top-line data building on prior interim data from January 2025 R&D Day and Alpha DaRT monotherapy studies across US, Europe, Israel, Japan.
Alpha DaRT designed as localized intratumoral add-on to standard pembrolizumab without altering systemic treatment.
Podium selection signifies high scientific merit and clinical significance in advancing head and neck oncology.